Skip to main content
. Author manuscript; available in PMC: 2019 Jul 16.
Published in final edited form as: J Vis Exp. 2019 Jan 16;(143):10.3791/58703. doi: 10.3791/58703

Figure 2: Illustrations for the preparation of 5× working solutions and the liquid transfer from the 96-well plate to the 384-well plate.

Figure 2:

(A) The 96-well plate layout of the 5× working solutions. Wells A1 to G2 have 300 μL per well of up to 15 5× working solutions and assay medium(M) as illustrated in columns 1 and 2. Compounds 14 and 15 are 2% DMSO and 25 μM 9-cis-retinal, respectively, for the treatment to the seven cell lines expressing WT and mutant rhodopsin. Additionally, columns 11 and 12 have 100 μL per well of 2% DMSO and 25 μM 9-cis-retinal controls, respectively, treated to the cells expressing the P23H rhodopsin for the calculation of Z’-factors. (B) The 384-well plate layout for cell type and treatment conditions. The U2OS cells expressing the WT, T4R, P23H, P53R, C110Y, D190N and P267L rhodopsin-Venus are seeded as illustrated. Treatment conditions are labeled in blue. Pink and blue tips demonstrate the well-to-well liquid transfer from the 96-well plate to the 384 plate using a multichannel pipette.